Juno Therapeutics Inc  

(Public, NASDAQ:JUNO)   Watch this stock  
Find more results for Juno
42.49
+0.06 (0.14%)
After Hours: 42.40 -0.09 (-0.21%)
Jan 29, 7:49PM EST  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 41.00 - 43.71
52 week 34.71 - 61.70
Open 42.16
Vol / Avg. 668,246.00/3.21M
Mkt cap 3.83B
P/E     -
Div/yield     -
EPS -2.24
Shares 90.43M
Beta     -
Inst. own 32%
Jan 14, 2015
Juno Therapeutics Inc at JPMorgan Healthcare Conference - Webcast
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -48.60% -
Return on average equity - -
Employees 70 -
CDP Score - -

Address

307 Westlake Ave N Ste 300
SEATTLE, WA 98109-5235
United States - Map
+1-206-6960703 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Juno Therapeutics, Inc. (Juno) is a United States-based clinical-stage biopharmaceutical company. The Company is engaged in developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR), and high-affinity T cell receptor (TCR), technologies to genetically engineer T cells to recognize and kill cancer cells. Through genetic engineering, the Company inserts a gene for a particular CAR or TCR construct into the T cell that enables it to better recognize cancer cells. Its CAR technology directs T cells to recognize cancer cells based on the expression of specific proteins located on the cell surface, whereas its TCR technology provides the T cells with a specific T cell receptor to recognize protein fragments derived from either the surface or inside the cell. The Company�s CD19 product candidates include JCAR015, JCAR017, and JCAR014. Its additional product candidates include CD22, L1CAM, MUC-16/IL-12, ROR-1 and WT-1.

Officers and directors

Howard H. Pien Chairman of the Board
Age: 57
Bio & Compensation  - Reuters
Hans Edgar Bishop President, Chief Executive Officer, Director
Age: 49
Bio & Compensation  - Reuters
Steven D. Harr M.D. Chief Financial Officer, Head of Corporate Development
Age: 44
Bio & Compensation  - Reuters
Mark W. Frohlich M.D. Executive Vice President - Research and Development
Age: 53
Bio & Compensation  - Reuters
Bernard J. Cassidy General Counsel, Secretary
Age: 60
Bio & Compensation  - Reuters
Hal V. Barron M.D. Director
Age: 50
Bio & Compensation  - Reuters
Richard Klausner M.D. Director
Age: 62
Bio & Compensation  - Reuters
Marc Tessier-Lavigne Ph.D. Director
Age: 54
Bio & Compensation  - Reuters
Anthony B. Evnin Ph.D. Independent Director
Age: 73
Bio & Compensation  - Reuters
Robert T. Nelsen M.D. Independent Director
Age: 51
Bio & Compensation  - Reuters